IceCure(ICCM) - 2023 Q3 - Earnings Call Transcript

Michael Polyviou Earlier today, we announced that we filed an appeal with the FDA requesting an additional review of IceCureÂ's De Novo classification request. Shay will provide more specific about the appeal in addition to sharing our regulatory pathway. Tlalit will also provide more insight into the impact of the independent study and how it helps our global commercial penetration. They will both be available to answer your questions during the Q&A session at the end of this call. Company Participants I w ...